Follow Us TR

News Details

Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin

About Oramed Pharmaceuticals Inc.
  • NASDAQ: $ORMP
  • Notified: $5.00
  • 08:56 EDT

Price Chart